These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 28219375)

  • 1. State of the art in anti-cancer mAbs.
    Chiavenna SM; Jaworski JP; Vendrell A
    J Biomed Sci; 2017 Feb; 24(1):15. PubMed ID: 28219375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Antibodies in Cancer Therapy.
    Gasser M; Waaga-Gasser AM
    Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor monoclonal antibodies in conjunction with β-glucans: a novel anti-cancer immunotherapy.
    Xiang D; Sharma VR; Freter CE; Yan J
    Curr Med Chem; 2012; 19(25):4298-305. PubMed ID: 22834812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer.
    Kaur N; Goyal A; Sindhu RK
    Anticancer Agents Med Chem; 2020; 20(16):1895-1907. PubMed ID: 32619180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
    Teng F; Kong L; Meng X; Yang J; Yu J
    Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale for anti-OX40 cancer immunotherapy.
    Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
    Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted cellular immunotherapy with bifunctional antibodies.
    Nelson H
    Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New solid tumor targets for therapeutic monoclonal antibodies.
    Papkoff J
    Expert Opin Ther Targets; 2007 May; 11(5):585-8. PubMed ID: 17465718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.
    Taylor RP; Lindorfer MA
    Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibodies against cancer].
    Barriuso Feijóo J; Sundlov A; González Barón M
    Rev Clin Esp; 2004 Dec; 204(12):649-54. PubMed ID: 15710074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.
    Marabelle A; Gray J
    Pediatr Blood Cancer; 2015 Aug; 62(8):1317-25. PubMed ID: 25808079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bi-specific antibody therapy for the treatment of cancer.
    Withoff S; Helfrich W; de Leij LF; Molema G
    Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor Antibodies Can Drive Therapeutic T Cell Responses.
    Wittrup KD
    Trends Cancer; 2017 Sep; 3(9):615-620. PubMed ID: 28867165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.